Skip to main content
. 2023 Jan 31;9(1):e002559. doi: 10.1136/rmdopen-2022-002559

Figure 3.

Figure 3

(A) PASI75 response rates†, (B) resolution rates of enthesitis‡, (C) resolution rates of dactylitis§, (D) change from baseline in HAQ-DI, (E) SF-36v2 PCS and (F) SF-36v2 MCS (full analysis set).¶†† The dotted line at/after month 3 indicates that patients in the placebo group were switched to tofacitinib 5 mg BID from month 3 for the remainder of the study. *p<0.05; **p<0.01; ***p<0.001 versus placebo (through month 3) or placebo→tofacitinib 5 mg BID (for remainder of study). †Assessed in patients with baseline psoriatic BSA ≥3% and baseline PASI >0. ‡Assessed in patients with baseline LEI >0, with resolution of enthesitis defined as LEI=0. §Assessed in patients with baseline DSS >0, with resolution of dactylitis defined as DSS=0. ¶All randomised patients who received ≥1 dose of study medication. ††For response outcomes, missing values were considered as non-response. For change from baseline, missing values were not imputed. ∆, change from baseline; BID, twice daily; BSA, body surface area; CI, confidence interval; DSS, Dactylitis Severity Score; HAQ-DI, Health Assessment Questionnaire-Disability Index; LEI, Leeds Enthesitis Index; M, month; MCS, Mental Component Summary; N, number of patients in full analysis set; N1, number of patients assessed; N2, number of patients with observations at study visit; n, number of patients meeting response criteria; PASI, Psoriasis Area and Severity Index; PBO, placebo; PCS, Physical Component Summary; SE, standard error; SF-36v2, Short Form-36 Health Survey version 2 acute; W, week.